About Us

At Shanghai Biotecan Pharmaceuticals Co. Ltd. our mission is to provide the best healthcare services through the most advanced technology. The company’s goal is to empower every medical professional and patient with specific knowledge to properly treat and prescribe patients symptoms and conditions through precision medicine. Biotecan uses strict quality management control system and strictly follows China’s GLP (Good Laboratory Practice of Drugs) standards. The company has International CAP Certification, and China’s Genetic Clinical Laboratory Certification (PCR).

Biotecan has an unparalleled team of experts from around the world in molecular diagnostics, medical big data, technology, engineering, and commercial development, making us a pioneer in precision medicine. Biotecan was founded in 2008, and currently owns 17 subsidiaries.

History
2008
  • Biotecan was founded in 2008
2009
  • Established Shanghai Pudong District’s first independent medical laboratory
2010
  • Granted "2010 Innovational Technology Project" Fund
2011
  • Established Shanghai Zhangjiang Translational Medical Research Center
2012
  • Cover of China’s Special Edition Issue - Established multicenter Clinical Research Center
  • Co-sponsored Zhanjiang Forum on Translational Medicine - Launched the “10x1000 Project”
2013
  • Founded Jining Jiu Genetic Modification Medical Research Corporation
  • Approved as a Shanghai High-Technology Company
  • Founded Biotecan Biomedicine Science and Technology Zhangjiakou Corporation
  • Established Zhangjiang Translational Medical Center in Second Military Medical University Medicine
  • Approved as Shanghai Medical Biomarker R&D and Industrialization of Public Service Platform
2014
  • Established Fudan-Zhangjiang Clinical Joint Molecular Research Center
  • Co-Sponsored with Sinopharm Group Co. Ltd. and built the National Medical Big Data Platform
  • Builds the National Independent Innovation Demonstration Zone Medical Big Data Public Service Platform
  • National Development and Reform Commission constructs "National Science and Medical Molecular Translational Center"
2015
  • National High Technology Research and Development - “863” Program (Biomedical Big Data Research and Development)
  • Launched the National Post-Doctoral Program at Biotecan
  • Established "Lung Cancer Precision Medicine Research and Development Center"
  • Established Fudan-Zhangjiang joint "Precision Medicine Big Data Center"
2016
  • Construction of Zhangjiang National Innovation Innovation Demonstration Zone Precision Medicine Big Data Platform
  • Establishment of Shanghai Precision Medicine Big Data Center
  • Honor of Shanghai “Four Innovation” Economic Innovation Base
2017
  • Establishment of first Biotecan Hi-tech Park——Dongyang Medical Union
  • Full score in EQA of High-throughput Sequencing for Tumor
  • Establishment of Shanghai Zhangjiang Medical Innovation Research Institute
2018
  • Identified as "2017 Pudong New Area Enterprise Research and Development Institution"
  • Honor of "Shanghai New Overseas Business Practice Base"
  • Contract with Dalian High-tech Zone and Huawei to jointly build "Dalian High-tech Zone Life Science Big Data Platform"
  • Settlement of Academician Yang Shengli Workstation in Biotecan
  • Honor of "Zhangjiang Innovation TOP100” and “Quasi-Unicorn Innovative Enterprise"
2019
  • Shanghai Biotecan Medical laboratory successfully passed the NGSST EQA of the College of American Pathologists (CAP)
  • Several times passed the 2019 EQA of the Clinic Center of Ministry of Health
  • Core technologies entering the fast track of patent application for innovative technologies
  • Shanghai Zhangjiang Medical Innovation Research Institute established The Intestinal Microecology Alliance with Shanghai 10th People's Hospital
  • Launched the first Project Roadshow of Shanghai Zhangjiang Medical Innovation Research Institute (Zhangjiang Pharmaceutical Union)
  • Honor of The Second Prize of Shanghai Intellectual Property Innovation Award for Core Technology Patent
Company Culture
Environment
Party
Benefits
Teams

Team of Experts

Dr. JINWEI LOU

Chairman of the Board

Executive Director at Zhangjiang Translational Medical Research and Development Center
Post-Doctorate at City of Hope National Medical Center
Awarded Distinguished Expert for the Shanghai “Pujiang Talent”

Dr. HUA YU

Professor at City of Hope National Medical Center

Director of Cancer Immunotherapy Project

Dr. CHENG XU

Professor at City of Hope National Medical Center

Director of Cancer Immunotherapy Project

Dr. LEMING SHI

Principal Investigator at FDA Toxicology Research Center

Professor at Fudan University

Dr. SHOUXIN WU

Fudan University

Director of Medical Department
Deputy Secretary of Zhongguancun Strategic Alliance of Innovative Technology for Pancreatic Disease

Dr. LING LIN

General manager of medical big data division

Doctor of Chinese Academy of Medical Sciences

Qualification Honor